Response to hydralazine-valproate in a patient with mycosis fungoides

Case Reports in Medicine

Volumn 2010, Issue , 2010, Pages

  Dueñas Gonzalez, Alfonso ^a   Vega, Maria Teresa ^a   Martinez Baños, Déborah ^b   Garciáa Hidalgo, Linda ^b   Sobrevilla, Pedro ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971335537     PISSN: 16879627     EISSN: 16879635     Source Type: Journal    
DOI: 10.1155/2010/657579     Document Type: Article

References (20)

1. E. Diamandidou, P. R. Cohen, and R. Kurzrock, "Mycosis fungoides and Sezary syndrome," Blood, vol. 88, no. 7, pp. 2385-2409, 1996.
2. J. M. Gardner, K. G. Evans, A. Musiek, et al., "Update on treatment of cutaneous T-cell lymphoma," Current Opinion in Oncology, vol. 21, no. 2, pp. 131-137, 2009.
3. J. S. Graham, S. B. Kaye, and R. Brown, "The promises and pitfalls of epigenetic therapies in solid tumours," European Journal of Cancer, vol. 45, no. 7, pp. 1129-1136, 2009.
4. L. Marquard, L. M. Gjerdrum, Ib. J. Christensen, et al., "Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous Tcell lymphoma," Histopathology, vol. 53, no. 3, pp. 267-277, 2008.
5. M. Duvic, R. Talpur, X. Ni, et al., "Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)," Blood, vol. 109, no. 1, pp. 31-39, 2007. (Pubitemid 46053039)
6. F. Foss, B. Pohlman, E. Jacobsen, et al., "Phase II open-label trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. EMSO Conference," Annals of Oncology, vol. 19, p. 154, 2008, abstract no. 241.
7. M. Demierre, S. Whittaker, Y. Kim, et al., "on behalf of all investigators. pooled analyses of two international, multicenter clinical studies of romidepsin in 167 patients with cutaneous T-cell lymphoma (CTCL)," Journal of Clinical Oncology, vol. 27, 2009, abstract no. 8546.
8. M. Prince, D. J. George, R. Johnstone, et al., "LBH589, a novel deacetylase inhibitor (DACi), treatment of patients with cutaneous T-cell lymphoma (CTCL). Skin gene expression profiles in the first 24 hours related to clinical response following therapy," Blood, vol. 108, 2006, abstract no. 2715.
9. R. van Doorn, W. H. Zoutman, R. Dijkman, et al., "Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73," Journal of Clinical Oncology, vol. 23, pp. 3886-3896, 2005. (Pubitemid 46218691)
10. C. Arce, C. Pérez-Plasencia, A. González-Fierro, et al., "A proof-of-principle study of epigenetics therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer," PLoS ONE, vol. 1, no. 1, article e98, 2006.
11. M. Candelaria, D. Gallardo-Rincón, C. Arce, et al., "A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors," Annals of Oncology, vol. 18, no. 9, pp. 1529-1538, 2007. (Pubitemid 47365487)
12. A. Duenas-Gonzalez, M. Candelaria, C. Perez-Plascencia, et al., "Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors," Cancer Treatment Reviews, vol. 34, no. 3, pp. 206-222, 2008.
13. F. Bellos and U. Mahlknecht, "Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients," Onkologie, vol. 31, no. 11, pp. 629-633, 2008.
14. A. Ryningen, C. Stapnes, P. Lassalle, et al., "A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid," Leukemia Research, vol. 33, no. 6, pp. 779-787, 2009.
15. T. Siitonen, T. Timonen, E. Juvonen, et al., "Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes," Haematologica, vol. 92, no. 8, pp. 1119-1122, 2007. (Pubitemid 350144220)
16. N. Singh, A. Dueñas-González, F. Lyko, and J. L. Medina-Franco, "Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1," ChemMedChem, vol. 4, no. 5, pp. 792-799, 2009.
17. A. Chavez-Blanco, C. Perez-Plasencia, E. Perez-Cardenas, et al., "Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines," Cancer Cell International, vol. 6, article 2, 2006.
18. M. Nakao, "Epigenetics: interaction of DNA methylation and chromatin," Gene, vol. 278, no. 1-2, pp. 25-31, 2001. (Pubitemid 33055776)
19. A. Dueñas-González, P. García-López, L. A. Herrera, et al., "The prince and the pauper. A tale of anticancer targeted agents," Molecular Cancer, vol. 7, article 82, 2008.
20. E. L. Tobinick, "The value of drug repositioning in the current pharmaceutical market," Drug News and Perspectives, vol. 22, no. 2, pp. 119-125, 2009.